The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia

BMC Psychiatry

Jingping Zhao¹  Renrong Wu¹  Hailong Lv¹  Qinling Wei²  Zhanchou Zhang¹  Xiaofeng Guo¹ 

[1] Institute of Mental Health, the Second Xiangya Hospital, Central South University, No. 139 Renmin Mid Road, Changsha, 410011, China;Department of Psychiatry, 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

关键词: Overweight;    Obesity;    Body mass index;    Cognitive function;    Schizophrenia;   

Others  :  1124085
DOI  :  10.1186/1471-244X-13-109

 received in 2012-11-24, accepted in 2013-03-27,  发布年份 2013

【 摘 要 】

Background

Studies have reported that up to 60% of individuals with schizophrenia are overweight or obese. This study explored the relationship between obesity and cognitive performance in Chinese patients with schizophrenia.

Methods

Outpatients with schizophrenia aged 18–50 years were recruited from 10 study sites across China. Demographic and clinical information was collected. A neuropsychological battery including tests of attention, processing speed, learning/memory, and executive functioning was used to assess cognitive function, and these 4 individual domains were transformed into a neurocognitive composite z score. In addition, height and weight were measured to calculate body mass index (BMI). Patients were categorized into 4 groups (underweight, normal weight, overweight and obese) based on BMI cutoff values for Asian populations recommended by the World Health Organization.

Results

A total number of 896 patients were enrolled into the study. Fifty-four percent of participants were overweight or obese. A higher BMI was significantly associated with lower scores on the Wechsler Memory Scale-Revised (WMS-R) Visual Reproduction subscale, the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol subscale, and the composite z score (p’s ≤ 0.024). Obese patients with schizophrenia had significantly lower scores than normal weight patients on the Trail Making Test B, the WMS-R Visual Reproduction subscale, the WAIS Digit Symbol subscale, and the composite z score (p’s ≤ 0.004).

Conclusions

Our study suggests that, in addition to its well established risk for various cardiometabolic conditions, obesity is also associated with decreased cognitive function in Chinese patients with schizophrenia. Future studies should explore if weight loss and management can improve cognitive function in obese patients who suffer from schizophrenia.

【 授权许可】

   
2013 Guo et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Green MF, Kern RS, Braff DL, Mintz J: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 2000, 26(1):119-136.
• [2]Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG: Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007, 64(10):1115-1122.
• [3]Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA: Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr Res 2004, 68(1):49-63.
• [4]Snitz BE, Macdonald AR, Carter CS: Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006, 32(1):179-194.
• [5]Susce MT, Villanueva N, Diaz FJ, de Leon J: Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 2005, 66(2):167-173.
• [6]Coodin S: Body mass index in persons with schizophrenia. Can J Psychiatry 2001, 46(6):549-555.
• [7]Catapano L, Castle D: Obesity in schizophrenia: what can be done about it? Australas Psychiatry 2004, 12(1):23-25.
• [8]Schwartz TL, Nihalani N, Jindal S, Virk S, Jones N: Psychiatric medication-induced obesity: a review. Obes Rev 2004, 5(2):115-121.
• [9]Tardieu S, Micallef J, Gentile S, Blin O: Weight gain profiles of new anti-psychotics: public health consequences. Obes Rev 2003, 4(3):129-138.
• [10]Muller DJ, Muglia P, Fortune T, Kennedy JL: Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004, 49(4):309-329.
• [11]Taki Y, Kinomura S, Sato K, Inoue K, Goto R, Okada K, Uchida S, Kawashima R, Fukuda H: Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity (Silver Spring) 2008, 16(1):119-124.
• [12]Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E: Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry 2007, 48(1):57-61.
• [13]Gunstad J, Spitznagel MB, Paul RH, Cohen RA, Kohn M, Luyster FS, Clark R, Williams LM, Gordon E: Body mass index and neuropsychological function in healthy children and adolescents. Appetite 2008, 50(2–3):246-251.
• [14]Gunstad J, Lhotsky A, Wendell CR, Ferrucci L, Zonderman AB: Longitudinal examination of obesity and cognitive function: results from the Baltimore longitudinal study of aging. Neuroepidemiology 2010, 34(4):222-229.
• [15]Cournot M, Marquie JC, Ansiau D, Martinaud C, Fonds H, Ferrieres J, Ruidavets JB: Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology 2006, 67(7):1208-1214.
• [16]Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, McIntyre RS: The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry 2012, 27(3):223-228.
• [17]Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC: Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013, 127(3):217-226.
• [18]Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223.
• [19]Saddichha S, Vishnuvardhan G, Akhtar S: Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia. Int J Risk Saf Med 2011, 23(3):181-185.
• [20]Guo X, Zhai J, Liu Z, Fang M, Wang B, Wang C, Hu B, Sun X, Lv L, Lu Z: Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry 2010, 67(9):895-904.
• [21]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
• [22]Wechsler D: The wechsler adult intelligence scale-revised. New York: Psychological Corp; 1981.
• [23]Reitan RM, Wolfson D: The halstead-reitan neuropsychological test battery: theory and clinical interpretation. 2nd edition. South Tucson, AriZ: Neuropsychology Press; 1993.
• [24]Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtis G: Wisconsin card sorting test manual. Odessa, Fla: Psychological Assessment Resources; 1993.
• [25]Wechsler D: The wechsler memory scale-revised. San Antonio, Tex: Psychological Corp; 1987.
• [26]Davidson J, Turnbull CD, Strickland R, Miller R, Graves K: The montgomery-asberg depression scale: reliability and validity. Acta Psychiatr Scand 1986, 73(5):544-548.
• [27]WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363(9403):157-163.
• [28]Howell DC: Statistical methods for psychology. 7th edition. Australia, Wadsworth: Cengage Learning; 2009.
• [29]Wang R, Wu MJ, Ma XQ, Zhao YF, Yan XY, Gao QB, He J: Body mass index and health-related quality of life in adults: a population based study in five cities of China. Eur J Public Health 2012, 22(4):497-502.
• [30]Convit A, Wolf OT, Tarshish C, de Leon MJ: Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci U S A 2003, 100(4):2019-2022.
• [31]Rahmouni K, Correia ML, Haynes WG, Mark AL: Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005, 45(1):9-14.
• [32]Ylikoski R, Ylikoski A, Raininko R, Keskivaara P, Sulkava R, Tilvis R, Erkinjuntti T: Cardiovascular diseases, health status, brain imaging findings and neuropsychological functioning in neurologically healthy elderly individuals. Arch Gerontol Geriatr 2000, 30(2):115-130.
• [33]Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L: The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 2010, 167(10):1232-1239.
• [34]Funahashi H, Yada T, Suzuki R, Shioda S: Distribution, function, and properties of leptin receptors in the brain. Int Rev Cytol 2003, 224:1-27.
• [35]Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K: Serum leptin level and cognition in the elderly: findings from the health ABC study. Neurobiol Aging 2009, 30(9):1483-1489.
• [36]Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
• [37]Hill SK, Bishop JR, Palumbo D, Sweeney JA: Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 2010, 10(1):43-57.
• [38]Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F: Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006, 368(9536):666-678.